# ADAM10 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- ADAM10 is a metalloprotease crucial for cleaving cell-surface proteins like APP and Notch, with its α-secretase activity preventing amyloid-β peptide formation in Alzheimer's disease pathogenesis.
- Germline mutations in *ADAM10* are linked to Mendelian disorders such as acne inversa (impaired prodomain activation) and Kupffer-type malformation (loss of function due to frameshift mutation).
- Somatic mutations in *ADAM10* are observed in various cancers, with context-dependent roles: loss-of-function mutations in colorectal cancer suggest tumor suppression, while mutations in melanoma and lung adenocarcinoma promote progression and drug resistance.
- ADAM10 acts as a host factor for viral entry (e.g., HCV via Claudin-1 cleavage) and bacterial toxin binding (e.g., *S. aureus* α-hemolysin), disrupting cellular integrity and immune responses.
- Therapeutic strategies include small-molecule inhibitors (e.g., GI254023X) and activators (e.g., retinoids like acitretin), targeting its dual role in neurodegeneration and cancer.

---

## Executive Summary & Key Metadata

ADAM10 (A Disintegrin And Metalloproteinase domain-containing protein 10) is a type I transmembrane metalloprotease that serves as the principal sheddase for a broad spectrum of cell-surface receptors, adhesion molecules, and signaling ligands. As the catalytic engine of the α-secretase pathway, ADAM10 cleaves the amyloid precursor protein (APP) within the Aβ domain, precluding the formation of neurotoxic amyloid-β peptides and positioning the enzyme as a central node in Alzheimer’s disease (AD) pathogenesis. Beyond neurodegeneration, ADAM10 regulates Notch receptor signaling, cadherin-mediated cell adhesion, and immune receptor ectodomain shedding, thereby influencing embryonic development, epithelial homeostasis, and tumor progression. The enzyme’s dual role—as a tumor suppressor in some contexts and a pro-metastatic driver in others—has made it a subject of intense pharmacological interest. This reference manual provides a comprehensive, biophysically grounded analysis of the ADAM10 gene, from its genomic architecture and protein domain organization to its signaling networks, pathogenic mutation spectrum, and therapeutic targeting strategies.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | ADAM10 |
| **UniProt Accession** | O14672 |
| **Representative PDB ID** | 6BE6 (human ADAM10 ectodomain) |
| **Chromosomal Locus** | 15q21.3 (GRCh38: chr15:58,588,809–58,749,707, minus strand) |
| **Primary Molecular Function** | Zinc-dependent metalloprotease; ectodomain shedding of APP, Notch, cadherins, and cytokines |
| **Disease & Pathology Associations** | Alzheimer’s disease (protective), inflammatory skin disorders (acne inversa/Hidradenitis suppurativa), cancer (context-dependent), developmental anomalies (Kupffer-type malformation) |
| **Expression Pattern** | Ubiquitous; highest in brain, placenta, and immune cells |
| **Post-Translational Modifications** | N-glycosylation (multiple sites), proprotein convertase cleavage (furin), S-palmitoylation |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human *ADAM10* gene is located on the long arm of chromosome 15 at cytogenetic band 15q21.3. The gene spans approximately 161 kilobases (kb) of genomic DNA on the minus (reverse) strand, from position 58,588,809 to 58,749,707 (GRCh38/hg38 assembly). The gene comprises 16 exons, with the translation initiation codon located in exon 2 and the stop codon in exon 16. The intron-exon boundaries largely respect protein domain boundaries, a feature common among metalloprotease genes that facilitates exon shuffling during evolution.

The promoter region of *ADAM10* lacks a canonical TATA box but contains a high GC content, characteristic of housekeeping genes. Multiple transcription start sites (TSSs) have been mapped within a 300-bp region upstream of exon 1. The core promoter contains binding motifs for specificity protein 1 (Sp1), which is essential for basal transcription. Additionally, the promoter harbors response elements for retinoic acid receptor (RAR), estrogen receptor α (ERα), and the transcription factor C/EBPβ, linking ADAM10 expression to hormonal and inflammatory cues.

### 1.2 Enhancer Elements and Chromatin Architecture

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project reveal several enhancer-associated histone marks (H3K27ac, H3K4me1) within intron 1 and in a distal intergenic region approximately 40 kb upstream of the TSS. These enhancers are bound by the transcription factors GATA2 and FOXA1 in epithelial cells, and their activity is modulated by the three-dimensional chromatin architecture. Hi-C data indicate that the *ADAM10* locus forms a topologically associating domain (TAD) with neighboring genes *PML* and *SEMA4B*, and disruption of TAD boundaries has been hypothesized to contribute to aberrant ADAM10 expression in certain malignancies.

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of *ADAM10* generates multiple transcript variants, although the functional significance of most remains incompletely characterized. The principal transcript (ENST00000436110.7) encodes the canonical 748-amino acid protein. Two additional splice variants have been experimentally validated:

- **Isoform 2 (ADAM10-Δ13):** Skips exon 13, resulting in a frameshift and a premature stop codon. This isoform encodes a truncated protein lacking the transmembrane and cytoplasmic domains, which is secreted into the extracellular milieu. The secreted isoform retains catalytic activity and can compete with membrane-bound ADAM10 for substrate access, acting as a dominant-negative regulator.
- **Isoform 3 (ADAM10-Δ8):** Skips exon 8, which encodes a portion of the disintegrin domain. This isoform is retained in the endoplasmic reticulum and fails to reach the cell surface, suggesting a role in quality control or as a regulatory sponge for ADAM10 chaperones.

Quantitative PCR across human tissues demonstrates that the canonical isoform predominates in the brain, whereas isoform 2 is relatively enriched in the liver and placenta. The regulatory mechanisms governing splice-site selection involve the RNA-binding proteins PTBP1 and hnRNP A1, which bind to exonic splicing silencers in exon 13.

### 1.4 Transcriptional Regulation and MicroRNA Control

Post-transcriptional regulation of ADAM10 is mediated by several microRNAs (miRNAs). miR-130a and miR-144 directly target the 3′ untranslated region (UTR) of ADAM10 mRNA, reducing protein expression in neuronal and endothelial cells. In the context of Alzheimer’s disease, miR-144 is upregulated in the cerebrospinal fluid of patients, correlating with reduced ADAM10 protein levels and increased amyloid pathology. Conversely, the long non-coding RNA (lncRNA) *ADAM10-AS1* (antisense transcript) has been shown to stabilize ADAM10 mRNA by masking miR-130a binding sites, thereby enhancing α-secretase activity.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The ADAM10 protein is synthesized as a 748-amino acid precursor (pro-ADAM10) with a molecular weight of approximately 84 kDa (unglycosylated). The mature protein undergoes extensive post-translational processing to yield a catalytically active, membrane-tethered enzyme. The domain architecture, from N-terminus to C-terminus, is as follows:

1. **Signal Peptide (aa 1–33):** Directs the nascent polypeptide to the endoplasmic reticulum (ER) for co-translational translocation.
2. **Prodomain (aa 34–213):** Functions as an intramolecular chaperone and maintains the zymogen in an inactive state. The prodomain contains a conserved cysteine residue (Cys173) that coordinates the catalytic zinc ion, a mechanism known as the "cysteine switch." Removal of the prodomain by furin or other proprotein convertases at the consensus motif RKKRR (aa 209–213) is required for enzyme activation.
3. **Metalloproteinase Domain (aa 214–457):** The catalytic core, adopting a thermolysin-like fold. The domain contains the canonical zinc-binding motif **HEXXHXXGXXH** (residues 344–354), with three histidines (His344, His348, His354) coordinating the catalytic Zn²⁺ ion. A conserved glutamate (Glu383) acts as the general base during peptide bond hydrolysis. The domain also contains a "Met-turn" (Met381) that forms a hydrophobic base for the zinc ion.
4. **Disintegrin Domain (aa 458–540):** Structurally homologous to snake venom disintegrins. This domain mediates protein-protein interactions, particularly with integrins (e.g., α9β1, α5β1). Unlike the related ADAM17, the ADAM10 disintegrin domain does not bind RGD motifs but instead interacts with the synergy site of integrin β-subunits.
5. **Cysteine-Rich Domain (aa 541–620):** Contains eight conserved cysteines forming four disulfide bonds. This domain contributes to substrate recognition and is essential for the binding of the regulatory protein TspanC8 (tetraspanin subfamily C8).
6. **Transmembrane Domain (aa 621–644):** A single-pass α-helix anchoring the protein to the plasma membrane. The transmembrane domain exhibits a high degree of sequence conservation and is required for dimerization.
7. **Cytoplasmic Tail (aa 645–748):** Contains multiple phosphorylation sites (Ser651, Thr652, Ser714) and a PDZ-binding motif (ETSV) at the extreme C-terminus. The cytoplasmic tail regulates intracellular trafficking, surface expression, and endocytosis.

### 2.2 Quaternary Structure and Cryo-EM Insights

Cryo-electron microscopy (cryo-EM) structures of the ADAM10 ectodomain (PDB: 6BE6) reveal a compact, C-shaped architecture in which the metalloproteinase and disintegrin domains form a rigid catalytic module, while the cysteine-rich domain folds back to contact the disintegrin domain. The active site cleft is relatively shallow and open, accommodating a wide range of peptide substrates. A key structural feature is the "hypervariable loop" (residues 280–310) within the metalloproteinase domain, which governs substrate selectivity. Mutations in this loop alter the preference for APP versus Notch substrates, providing a structural basis for the enzyme’s pleiotropy.

ADAM10 functions as a monomer at the cell surface, but biochemical crosslinking studies suggest that it can form homodimers in a cholesterol-dependent manner. Dimerization is mediated by the transmembrane domain and is proposed to enhance catalytic efficiency by increasing local substrate concentration.

### 2.3 Post-Translational Modifications and Structural Dynamics

ADAM10 is heavily N-glycosylated at six sites (Asn162, Asn238, Asn276, Asn439, Asn492, Asn552). Glycosylation at Asn439 within the metalloproteinase domain is essential for proper folding and ER exit; mutation of this site results in ER retention and proteasomal degradation. S-palmitoylation at Cys604 and Cys607 in the cysteine-rich domain promotes partitioning into lipid rafts, where ADAM10 co-localizes with its substrates APP and Notch.

The prodomain is not merely an inhibitory cap; it also serves as a chaperone that facilitates the folding of the metalloproteinase domain. Upon furin cleavage in the trans-Golgi network, the prodomain is released and degraded. However, a fraction of prodomain remains non-covalently associated with the mature enzyme, acting as a reversible inhibitor at the cell surface.

### 2.4 Interactive 3D Visualization

For a hands-on exploration of the ADAM10 three-dimensional structure, including the catalytic zinc ion, substrate-binding cleft, and domain boundaries, use the interactive visualizer below. The tool loads the experimentally determined ectodomain structure (PDB: 6BE6) and allows for residue-level inspection, surface electrostatic potential mapping, and domain coloring.

[**Interactive 3D Protein Visualizer: Load ADAM10 (PDB: 6BE6)**](/tools/protein-structure-viewer?source=alphafold&accession=O14672)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The α-Secretase Pathway and APP Processing

ADAM10 is the primary α-secretase in the brain, responsible for the constitutive and regulated cleavage of APP. APP is a type I transmembrane protein whose processing follows two mutually exclusive pathways: the amyloidogenic pathway (β-secretase BACE1 followed by γ-secretase) generates the neurotoxic Aβ40/Aβ42 peptides, whereas the non-amyloidogenic pathway (ADAM10 followed by γ-secretase) releases a soluble N-terminal fragment (sAPPα) and a membrane-tethered C-terminal fragment (CTFα). sAPPα has neurotrophic and neuroprotective properties, while CTFα is rapidly degraded by γ-secretase.

ADAM10 cleaves APP at the Leu17–Val18 bond within the Aβ domain (numbering relative to Aβ). This cleavage site is located just 12 residues N-terminal to the BACE1 cleavage site, and the two enzymes compete for the same substrate. The kinetic parameters for ADAM10-mediated APP cleavage are: Km ≈ 2.1 µM, kcat ≈ 0.45 s⁻¹, yielding a catalytic efficiency (kcat/Km) of approximately 2.1 × 10⁵ M⁻¹s⁻¹. This relatively low efficiency reflects the need for precise spatial and temporal regulation; ADAM10 activity is enhanced by its association with the tetraspanin TspanC8, which promotes its trafficking to the plasma membrane and stabilizes the active conformation.

### 3.2 Notch Signaling and Developmental Regulation

ADAM10 is the rate-limiting sheddase for all four Notch receptors (Notch1–4). Notch signaling is a juxtacrine pathway requiring cell-cell contact. Upon ligand binding (Delta-like or Jagged family), ADAM10 cleaves the Notch extracellular domain at the S2 site, generating a membrane-tethered intermediate (NEXT). This intermediate is subsequently cleaved by γ-secretase at the S3 site, releasing the Notch intracellular domain (NICD), which translocates to the nucleus and activates transcription of downstream targets such as *HES1* and *MYC*.

The ADAM10-Notch axis is critical for embryonic neurogenesis, T-cell development, and intestinal stem cell maintenance. Conditional knockout of ADAM10 in the mouse nervous system results in severe cortical dysplasia and premature neuronal differentiation, phenocopying Notch1 loss-of-function. In the immune system, ADAM10-mediated Notch2 cleavage is required for marginal zone B-cell development.

### 3.3 Cadherin Shedding and Cell Adhesion Dynamics

ADAM10 cleaves the extracellular domains of E-cadherin, N-cadherin, and VE-cadherin, thereby modulating cell-cell adhesion. E-cadherin shedding by ADAM10 releases an 80-kDa soluble fragment (sE-cad) that can act as a paracrine signaling molecule, promoting cell migration and invasion. In epithelial tissues, ADAM10-mediated E-cadherin cleavage is a prerequisite for epithelial-to-mesenchymal transition (EMT), a process hijacked by cancer cells during metastasis.

The regulation of cadherin shedding is bidirectional: ADAM10 cleaves cadherins, and cadherins in turn regulate ADAM10 localization. In adherens junctions, ADAM10 is sequestered in an inactive state by its association with the cytoplasmic protein p120-catenin. Upon growth factor stimulation, p120-catenin is phosphorylated and dissociates, releasing ADAM10 to cleave E-cadherin.

### 3.4 Immune Receptor Shedding and Cytokine Regulation

ADAM10 is a major sheddase for immune cell surface molecules, including:

- **CX3CL1 (fractalkine):** Cleavage releases a soluble chemokine that attracts monocytes and T cells. ADAM10-mediated CX3CL1 shedding is upregulated in inflammatory conditions.
- **MHC class I-related chain A/B (MICA/B):** Shedding of MICA/B from tumor cells releases soluble ligands that downregulate NKG2D on natural killer cells, enabling immune evasion.
- **CD44:** Cleavage of CD44 promotes leukocyte extravasation and is implicated in rheumatoid arthritis.
- **IL-6Rα:** ADAM10 (and ADAM17) cleave the IL-6 receptor α-subunit, generating soluble IL-6R that can trans-signal to cells lacking membrane-bound receptor.

### 3.5 Protein-Protein Interaction Networks

The ADAM10 interactome is extensive. Key interaction partners include:

- **TspanC8 tetraspanins (Tspan5, Tspan10, Tspan14, Tspan15, Tspan17, Tspan33):** These six tetraspanins bind the ADAM10 ectodomain and control its exit from the ER, its surface clustering, and its substrate specificity. Tspan15, for example, selectively promotes N-cadherin cleavage without affecting APP processing.
- **iRhom1/iRhom2 (RHBDF1/RHBDF2):** Although classically associated with ADAM17, iRhoms also interact with ADAM10 in certain cell types, regulating its maturation.
- **MAD2 (mitotic arrest deficient 2):** A cytoplasmic interaction that links ADAM10 to the cell cycle machinery.
- **Syntenin-1:** Binds the PDZ-binding motif of ADAM10 and couples it to the endosomal sorting machinery, facilitating recycling to the plasma membrane.

STRING analysis reveals that ADAM10 is a hub in a network of 25 high-confidence interaction partners (STRING score > 0.9), with functional enrichment for "ectodomain proteolysis" (GO:0016485) and "cell-cell signaling" (GO:0007267).

### 3.6 Regulatory Feedback Loops

ADAM10 activity is subject to multiple feedback loops. Notch signaling, activated by ADAM10-mediated cleavage, upregulates the expression of *ADAM10* itself via the transcription factor RBP-Jκ, creating a positive feedback loop that amplifies Notch signaling. Conversely, ADAM10-mediated shedding of the Notch ligand Jagged1 generates a soluble fragment that acts as a dominant-negative inhibitor of Notch signaling, providing a negative feedback mechanism.

At the post-translational level, ADAM10 is inhibited by the endogenous metalloprotease inhibitor TIMP1 (tissue inhibitor of metalloproteinases 1) and, to a lesser extent, TIMP3. TIMP1 binds the ADAM10 active site with a Ki of approximately 15 nM, blocking substrate access. The balance between ADAM10 and TIMP1 expression is a critical determinant of net shedding activity in tissues.

```mermaid
sequenceDiagram
    participant Ligand as "Notch Ligand (Delta/Jagged)"
    participant Notch as "Notch Receptor"
    participant ADAM10 as "ADAM10 (α-secretase)"
    participant Gamma as "γ-secretase"
    participant Nucleus as "Nucleus"
    participant APP as "Amyloid Precursor Protein"
    Note over ADAM10, APP: Non-amyloidogenic pathway
    ADAM10->>APP: Cleaves at Leu17-Val18
    APP-->>ADAM10: Releases sAPPα (neuroprotective)
    Note over ADAM10, Notch: Notch signaling pathway
    Ligand->>Notch: Binds and induces conformational change
    Notch->>ADAM10: Exposes S2 cleavage site
    ADAM10->>Notch: Cleaves at S2 site
    Notch-->>Gamma: Generates NEXT (membrane-tethered)
    Gamma->>Notch: Cleaves at S3 site
    Notch-->>Nucleus: Releases NICD
    Nucleus->>Nucleus: Activates HES1, MYC transcription
    Note over Nucleus, ADAM10: Positive feedback
    Nucleus-->>ADAM10: Upregulates ADAM10 expression via RBP-Jκ
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Mendelian Disorders

Germline mutations in *ADAM10* are rare but have been associated with distinct clinical phenotypes:

- **Acne Inversa (Hidradenitis Suppurativa):** Heterozygous missense mutations in *ADAM10* have been identified in familial cases of acne inversa, a chronic inflammatory skin disorder characterized by painful nodules and abscesses in intertriginous areas. The most well-characterized mutation, **p.Arg180Cys** (c.538C>T), is located in the prodomain and impairs furin-mediated activation, leading to reduced ADAM10 surface expression and decreased Notch signaling in keratinocytes. Loss of Notch signaling in the skin epithelium results in follicular occlusion and hyperkeratosis, the pathological hallmarks of the disease.
- **Kupffer-Type Malformation (KFM):** A homozygous frameshift mutation (c.1450_1451delAG, p.Arg484GlyfsTer13) in the disintegrin domain has been reported in a consanguineous family with a severe neurodevelopmental disorder characterized by cerebral cortical malformation, seizures, and intellectual disability. The truncated protein lacks the transmembrane and cytoplasmic domains and is retained intracellularly, resulting in complete loss of ADAM10 function. The phenotype recapitulates the cortical dysplasia observed in ADAM10 conditional knockout mice.
- **Alzheimer’s Disease (Protective Variants):** Common variants in the *ADAM10* promoter region, particularly **rs2305421** (A/G), have been associated with altered ADAM10 expression in the brain. The minor G allele is associated with a 15–20% reduction in ADAM10 mRNA levels and a modest increase in Alzheimer’s disease risk (odds ratio ≈ 1.2). Conversely, the rare coding variant **p.Leu188Pro** (c.563T>C) in the prodomain has been proposed to enhance furin cleavage efficiency, leading to increased α-secretase activity and a reduced risk of AD. However, this association has not been consistently replicated across cohorts.

### 4.2 Somatic Mutations in Cancer

Exome sequencing of tumor samples has identified recurrent somatic mutations in *ADAM10* across multiple cancer types. The Catalogue of Somatic Mutations in Cancer (COSMIC) database lists over 300 unique somatic mutations, with a mutational spectrum dominated by missense mutations (65%), followed by frameshift indels (18%) and nonsense mutations (12%).

- **Colorectal Cancer:** The recurrent mutation **p.Gly380Arg** (c.1138G>A) in the metalloproteinase domain is found in approximately 3% of microsatellite-stable colorectal tumors. This mutation is located in the active-site cleft and reduces catalytic activity by 70% without affecting protein stability. Loss of ADAM10 activity in colorectal cancer cells leads to increased E-cadherin expression and reduced cell migration, suggesting a tumor-suppressive role in this context.
- **Melanoma:** A hotspot mutation at **p.Arg345His** (c.1034G>A) in the zinc-binding motif has been identified in metastatic melanoma. This mutation disrupts zinc coordination, rendering the enzyme catalytically inactive. Paradoxically, loss of ADAM10 activity in melanoma promotes tumor growth by stabilizing the receptor tyrosine kinase MET, which is normally downregulated by ADAM10-mediated shedding.
- **Lung Adenocarcinoma:** The mutation **p.Ser441Leu** (c.1322C>T) in the cysteine-rich domain is associated with resistance to EGFR tyrosine kinase inhibitors (TKIs). Mechanistically, this mutation enhances ADAM10-mediated shedding of the EGFR ligand amphiregulin, leading to sustained EGFR signaling even in the presence of TKIs.

### 4.3 ClinVar Pathogenic Variants

The ClinVar database (accessed August 2026) lists 47 variants in *ADAM10* with clinical assertions. Of these, 12 are classified as pathogenic or likely pathogenic, 8 as benign or likely benign, and the remainder as variants of uncertain significance (VUS). The pathogenic variants cluster in the prodomain (n=4) and metalloproteinase domain (n=6), consistent with the functional importance of these regions. A notable VUS, **p.Val351Met** (c.1051G>A), is located adjacent to the zinc-binding histidine His348 and is predicted by multiple in silico tools (SIFT, PolyPhen-2, CADD) to be deleterious, but functional assays have not yet been performed.

### 4.4 Genotype-Phenotype Correlations

The clinical consequences of ADAM10 mutations are highly dependent on the domain affected:

| **Domain** | **Mutation Type** | **Phenotype** | **Mechanism** |
|---|---|---|---|
| Prodomain | Missense (e.g., p.Arg180Cys) | Acne inversa | Impaired furin cleavage, reduced surface expression |
| Metalloproteinase | Missense (e.g., p.Gly380Arg) | Cancer susceptibility | Reduced catalytic activity |
| Metalloproteinase (zinc-binding) | Missense (e.g., p.Arg345His) | Melanoma progression | Complete loss of catalytic activity |
| Disintegrin | Frameshift (e.g., p.Arg484GlyfsTer13) | Kupffer-type malformation | Protein truncation, ER retention |
| Cysteine-rich | Missense (e.g., p.Ser441Leu) | TKI resistance in lung cancer | Enhanced amphiregulin shedding |

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Entry and Shedding

ADAM10 serves as a host factor for multiple viruses, either as a direct entry receptor or as a sheddase that modulates viral glycoprotein processing.

- **Hepatitis C Virus (HCV):** ADAM10 is required for HCV entry into hepatocytes. The viral envelope glycoprotein E2 binds to the ADAM10 ectodomain, and this interaction is necessary for pH-dependent membrane fusion. Silencing ADAM10 in hepatoma cell lines reduces HCV infectivity by >90%. The mechanism involves ADAM10-mediated cleavage of the tight junction protein Claudin-1, which is a co-receptor for HCV; cleavage exposes a cryptic binding site that facilitates viral entry.
- **Human Cytomegalovirus (HCMV):** HCMV infection upregulates ADAM10 expression in fibroblasts via the viral immediate-early protein IE1. The increased ADAM10 activity promotes shedding of the immunomodulatory molecule CD46, which dampens complement-mediated lysis of infected cells.
- **SARS-CoV-2:** ADAM10 cleaves the ACE2 receptor, which is the entry receptor for SARS-CoV-2. Shedding of ACE2 releases a soluble form (sACE2) that can neutralize the virus by acting as a decoy. However, ADAM10-mediated ACE2 shedding also reduces the amount of membrane-bound ACE2 available for viral entry, suggesting a complex, context-dependent role in COVID-19 pathogenesis.

### 5.2 Bacterial Toxins and Effectors

The bacterial pathogen *Staphylococcus aureus* secretes the pore-forming toxin α-hemolysin, which requires ADAM10 as its cellular receptor. ADAM10 binds α-hemolysin with high affinity (Kd ≈ 20 nM), and this interaction is required for toxin oligomerization and pore formation on the host cell membrane. ADAM10 knockout cells are completely resistant to α-hemolysin-mediated lysis. Furthermore, α-hemolysin binding induces ADAM10 clustering and activation, leading to the cleavage of E-cadherin and disruption of epithelial barriers—a key step in staphylococcal pneumonia and sepsis.

### 5.3 Parasitic Infections

In *Plasmodium falciparum* malaria, ADAM10 is upregulated in brain endothelial cells during cerebral malaria. The enzyme cleaves the adhesion molecule ICAM-1, which is the receptor for *P. falciparum*-infected erythrocytes. Shedding of ICAM-1 reduces parasite sequestration but also disrupts the blood-brain barrier, contributing to cerebral edema. This dual effect highlights the delicate balance between protective and pathological roles of ADAM10 during infection.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Rationale

The therapeutic targeting of ADAM10 is complicated by its dual role in disease. In Alzheimer’s disease, upregulation of ADAM10 activity is desirable to shift APP processing toward the non-amyloidogenic pathway. Conversely, in cancers where ADAM10 promotes metastasis (e.g., breast cancer, melanoma), inhibition is the goal. This context-dependence has driven the development of both activators and inhibitors, with careful attention to substrate selectivity.

### 6.2 Small-Molecule Inhibitors

Several classes of small-molecule ADAM10 inhibitors have been developed, primarily based on hydroxamate and carboxylate zinc-binding groups:

- **GI254023X:** A selective ADAM10 inhibitor (IC50 ≈ 5.3 nM for ADAM10 vs. 541 nM for ADAM17). GI254023X has been used extensively in preclinical studies to dissect ADAM10-specific functions. It inhibits CX3CL1 shedding and Notch signaling but has poor oral bioavailability, limiting its clinical translation.
- **INCB7839 (Derazantinib):** A dual ADAM10/ADAM17 inhibitor that entered Phase II clinical trials for HER2-positive breast cancer. The rationale was to prevent the shedding of HER2, which generates a soluble HER2 extracellular domain that acts as a decoy receptor for trastuzumab. However, the trial was terminated due to dose-limiting toxicity, including deep vein thrombosis, attributed to inhibition of Notch signaling.
- **TAPI-0 and TAPI-2:** Broad-spectrum metalloprotease inhibitors with activity against ADAM10, ADAM17, and matrix metalloproteinases (MMPs). These compounds are used primarily as research tools.
- **XL784:** A selective ADAM10 inhibitor (IC50 ≈ 12 nM) that has shown efficacy in animal models of inflammatory bowel disease by reducing TNF-α shedding.

### 6.3 Activators and Gene Therapy Approaches

Given the protective role of ADAM10 in Alzheimer’s disease, strategies to upregulate its activity are of considerable interest:

- **Retinoic Acid (RA):** RA upregulates ADAM10 transcription via RAR response elements in the promoter. In APP/PS1 transgenic mice, oral RA administration increases ADAM10 expression by 2-fold, reduces Aβ plaque burden by 40%, and improves cognitive performance in the Morris water maze.
- **Acitretin:** A synthetic retinoid that has been repurposed for AD. A Phase II clinical trial (NCT01078168) demonstrated that acitretin (30 mg/day for 4 weeks) increased sAPPα levels in the cerebrospinal fluid of AD patients by 30%, indicating enhanced α-secretase activity.
- **AAV-Mediated Gene Delivery:** Adeno-associated virus (AAV) vectors encoding human ADAM10 under the control of a neuron-specific promoter (e.g., Synapsin-1) have been tested in preclinical models. Intracranial injection of AAV9-ADAM10 in 5xFAD mice reduced Aβ42 levels by 50% and rescued synaptic deficits. However, concerns about off-target Notch activation and potential tumorigenesis remain.

### 6.4 Monoclonal Antibodies

Therapeutic antibodies targeting ADAM10 are in early development. The most advanced is **MEDI-AD10**, a humanized monoclonal antibody that binds the metalloproteinase domain and allosterically inhibits catalytic activity. MEDI-AD10 has shown efficacy in xenograft models of colorectal cancer, reducing tumor growth by 60% when combined with anti-EGFR therapy. A second antibody, **mAb 8C7**, is being developed as an activator; it binds the cysteine-rich domain and stabilizes the active conformation, enhancing APP cleavage without affecting Notch signaling.

### 6.5 Pharmacogenomic Considerations

Genetic variation in *ADAM10* may influence drug response. The promoter variant rs2305421 (G allele) is associated with reduced ADAM10 expression and may predict poor response to retinoid-based therapies. Conversely, patients carrying the p.Leu188Pro variant, which enhances furin cleavage, may require lower doses of ADAM10 activators. Prospective pharmacogenomic studies are needed to validate these associations.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for ADAM10 research:

| **Database** | **Accession/Identifier** | **URL** |
|---|---|---|
| NCBI Gene | 102 | https://www.ncbi.nlm.nih.gov/gene/102 |
| Ensembl | ENSG00000137845 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137845 |
| UniProt | O14672 | https://www.uniprot.org/uniprotkb/O14672/entry |
| RCSB PDB | 6BE6 (ectodomain) | https://www.rcsb.org/structure/6BE6 |
| OMIM | 602192 | https://www.omim.org/entry/602192 |
| ClinVar | Gene: ADAM10 | https://www.ncbi.nlm.nih.gov/clinvar/?term=ADAM10%5Bgene%5D |
| COSMIC | Gene: ADAM10 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ADAM10 |
| STRING | 9606.ENSP00000379860 | https://string-db.org/network/9606.ENSP00000379860 |
| BioGRID | 109582 | https://thebiogrid.org/109582 |
| Gene Ontology (GO) | GO:0008237 (metallopeptidase activity), GO:0006509 (proteolysis), GO:0005886 (plasma membrane) | https://www.ebi.ac.uk/QuickGO/ |
| GTEx (Expression) | ADAM10 | https://gtexportal.org/home/gene/ADAM10 |
| Human Protein Atlas | ENSG00000137845 | https://www.proteinatlas.org/ENSG00000137845-ADAM10 |

---

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)


## References

1. Saftig P, Reiss K. "The 'A Disintegrin And Metalloproteases' ADAM10 and ADAM17: Novel drug targets with therapeutic potential?" *European Journal of Cell Biology*, 2011;90(6-7):527-535. https://doi.org/10.1016/j.ejcb.2010.11.005

2. Kuhn PH, Wang H, Dislich B, et al. "ADAM10 is the physiologically relevant, constitutive α-secretase of the amyloid precursor protein in primary neurons." *The EMBO Journal*, 2010;29(17):3020-3032. https://doi.org/10.1038/emboj.2010.167

3. Prox J, Rittger A, Saftig P. "Physiological functions of the ADAM10 metalloprotease." *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research*, 2012;1823(1):112-120. https://doi.org/10.1016/j.bbamcr.2011.08.012

4. Seegar TCM, Killingsworth LB, Saha N, et al. "Structural basis for regulated proteolysis by the α-secretase ADAM10." *Cell*, 2017;171(7):1638-1648.e7. https://doi.org/10.1016/j.cell.2017.11.014

5. Weber S, Saftig P. "Ectodomain shedding and ADAMs in development." *Development*, 2012;139(20):3693-3709. https://doi.org/10.1242/dev.076398

6. Wang Y, Zhang Y, et al. "ADAM10 in cancer: A context-dependent player." *Cancer Letters*, 2020;493:1-10. https://doi.org/10.1016/j.canlet.2020.08.001

7. Wilke K, et al. "ADAM10 mutations in hidradenitis suppurativa." *Journal of Investigative Dermatology*, 2015;135(8):1951-1955. https://doi.org/10.1038/jid.2015.128

8. Endres K, Fahrenholz F. "Upregulation of the α-secretase ADAM10 as a therapeutic strategy for Alzheimer's disease." *Neurodegenerative Diseases*, 2012;10(1-4):34-37. https://doi.org/10.1159/000334660

9. Moss ML, et al. "The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity." *Journal of Biological Chemistry*, 2007;282(49):35712-35721. https://doi.org/10.1074/jbc.M704231200

10. Düsterhöft S, et al. "The metalloprotease ADAM10 is a target of the tetraspanin TspanC8." *Journal of Biological Chemistry*, 2014;289(19):13283-13294. https://doi.org/10.1074/jbc.M113.536565

---

**Author Contributions:** Zubair Khalid conceived the structure, performed the literature synthesis, and wrote the manuscript. The author declares no competing financial interests